Related Experiment Video

Updated: Apr 7, 2026

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.6K

SHaRe: advancing the goal of effective treatment for cardiomyopathy

Jonathan C Fox

    European Heart Journal
    |July 15, 2015
    PubMed

    Insights

    The Sarcomeric Human Cardiomyopathy Registry (SHaRe) is a new initiative for collecting data on this heart condition. This registry aims to improve understanding and treatment of sarcomeric human cardiomyopathies.

    Area of Science:

    • Cardiology
    • Genetics
    • Medical Registries

    Background:

    • Sarcomeric human cardiomyopathies are a group of inherited heart muscle diseases.
    • Understanding the genetic basis and clinical progression is crucial for effective management.

    Discussion:

    • Dr. Jonathon C. Fox discusses the establishment and goals of the Sarcomeric Human Cardiomyopathy Registry (SHaRe).
    • The registry aims to centralize patient data for research and clinical insights.

    Key Insights:

    • SHaRe will facilitate comprehensive data collection on sarcomeric cardiomyopathies.
    • This initiative supports research into disease mechanisms and patient outcomes.

    Outlook:

    • The registry is expected to enhance diagnostic accuracy and therapeutic strategies.
    • Long-term data from SHaRe will be invaluable for understanding disease trajectories.

    More Related Videos

    Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix09:11

    Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

    Published on: September 22, 2014

    12.5K
    Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model07:20

    Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model

    Published on: February 10, 2023

    1.8K

    Related Concept Videos

    Cardiomyopathy V: Interprofessional Care01:29

    Cardiomyopathy V: Interprofessional Care

    Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
    664
    Cardiomyopathy II: Dilated Cardiomyopathy01:30

    Cardiomyopathy II: Dilated Cardiomyopathy

    Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
    776
    Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

    Cardiomyopathy III: Hypertrophic Cardiomyopathy

    Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
    741
    Myocarditis III: Medical Management01:14

    Myocarditis III: Medical Management

    Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
    324
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    1.9K
    Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

    Cardiomyopathy IV: Restrictive Cardiomyopathy

    Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
    852